Vol. 1: *Biologically Active Atrial Peptides*

Vol. 2: *Advances in Atrial Peptide Research*
Advances in Atrial Peptide Research

Editors

Barry M. Brenner, M.D.

Director, Renal Division
Department of Medicine
Brigham and Women's Hospital
and Harvard Medical School
Boston, Massachusetts

John H. Laragh, M.D.

Director, Cardiovascular Center
and Department of Medicine
Cornell University Medical College
New York, New York

Raven Press New York
Acknowledgments

The Editors are privileged to have again played a role in the organizational and scientific aspects of the Second World Congress and wish to express their gratitude to the many authors for their excellent contributions and splendid cooperation. We also gratefully acknowledge the invaluable efforts of the many professionals at Wyeth-Ayerst Laboratories and Raven Press, without whose interest and support these scientific proceedings would not be possible.
Contents

Preface v
Contributors xix
Author Index xxiii

Chapters

1 Frontiers in Biologically Active Atrial Peptides 1
   J. Genest, M. Cantin, P. Larochelle, and M. Nemer

2 Hormonal Regulation of the Gene for Atrial Natriuretic Factor 9
   D. G. Gardner, M. C. LaPointe, J. Wu, J. D. Baxter, and B. J. Gertz

3 Biochemical Studies on the Processing of Pro-ANF and Complete Purification and Characterization of Two Distinct Forms of ANF Receptors 15

4 Physiological Role of Atrial Natriuretic Factor Receptors 25

5 Pharmacological and Biochemical Studies of Atrial Natriuretic Peptide Receptor Subpopulations 31

6 Cloning and Expression of the Receptor for Atrial Natriuretic Peptide 41
   J. Gordon Porter, F. Fuller, D. B. Schenk, A. Arfsten, and J. A. Lewicki

7 Atrial Natriuretic Peptide Receptor Number and Affinity Are Decreased in Cultured Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats 45
8 Role of Guanylate Cyclase and Cyclic GMP in the Actions of ANF  
F. Murad, D. C. Leitman, B. M. Bennett, C. Molina, and S. A. Waldman

9 Mediatroy Role of Cyclic GMP in Receptor-Mediated Signal Transduction: Membrane Guanylate Cyclase and Its Coupling with Atrial Natriuretic Factor Receptor  
R. K. Sharma, R. B. Marala, and A. K. Paul

10 Atrial Natriuretic Factor Inhibits Angiotensin II and Phorbolester-Induced Activation of Protein Kinase C in Vascular Smooth Muscle Cells  
C. Tamm, U. Lang, and M. B. Vallotton

11 Release of Atrial Natriuretic Peptide—Physical Stretch or Central Reflex?  
H. Sonnenberg

12 The In Vivo Vascular Actions of Atrial Natriuretic Factor  
R. W. Lappe

13 The Physiologic Role of Atrial Natriuretic Peptide in Acute Volume Expansion  
T. A. Fried and J. H. Stein

14 Direct Transport Effects of Atrial Natriuretic Peptides in Inner Medullary Collecting Duct Cells  
M. L. Zeidel

15 The Renal, Urinary Cyclic GMP and Endocrine Effects of Changing Plasma Atrial Natriuretic Peptide Concentrations Within the Physiological Range by Infusion of Exogenous Synthetic ANP in Humans  
J. V. Anderson, N. D. Millar, A. C. Williams, J. D. H. Slater, and S. R. Bloom

16 ANF as a Regulator of Sodium and Water in Congestive Heart Failure  
R. J. Cody, S. A. Atlas, and J. H. Laragh

17 Atrial Natriuretic Factor in Congestive Heart Failure  
J. C. Burnett, Jr.

18 Neuropeptide Y Is Intrinsic to the Heart  
J. M. Allen, J. B. Martin, and G. Heinrich
Extended Abstracts

Section I: ANP Synthesis, Storage, Release, and Radioimmunoassays

Prepro-ANF_{56-92}-Like Immunoreactive Material: A Novel Hormone Candidate in Rat Atrium 161

Release of Biologically Active Atrial Natriuretic Factor (ANF) from the Rat Lungs 165
J. Gutkowska and P. Sirois

Alpha-Human Natriuretic Peptide Release in Normal Humans: Effects of Postural Changes and Blood Volume Load 169
L. Malatino, C. Zoccali, B. Stancaelli, G. Tonolo, G. Greco, F. Guzzardi, F. Mallamaci, and G. Tamburino

Dynorphin A 1–10 Amide Stimulated the Release of Atrial Natriuretic Polypeptide from Rat Atrium 171
J. Tang, C. W. Xie, X. Z. Xie, X. M. Gao, and J. K. Chang

Co-secretion of N-Terminal Fragment of Gamma-Human ANP, N-Peptide with Alpha-Human ANP and its Metabolism in Humans 174

Beta-Human Atrial Natriuretic Polypeptide (β-Human ANP) Is Converted into Alpha-Human ANP in Human Circulation In Vivo 179

Molecular Heterogeneity of Immunoreactive Atrial Natriuretic Peptides in Human Plasma 183

Presence of the N-Terminal Portion of Pro-Atrial Natriuretic Factor (ANF) in the Rat and Human Circulation 187
G. Thibault, P. Larochelle, R. Garcia, and M. Cantin

Preparation and Characterization of a Monoclonal Antibody to Alpha-Human Atrial Natriuretic Polypeptide 191

Immunoeextraction and RIA of Atrial Natriuretic Peptide from Human Plasma Samples 195

Radioreceptor and Radioimmunoassay Measurement of Atrial Natriuretic Peptide in Human Plasma 199
G. A. Sagnella, M. G. Buckley, N. D. Markandu, and G. A MacGregor

An Enzyme-Linked Immunosorbent Assay (ELISA) for Determination of Atrial Natriuretic Peptide (ANP) in Human Plasma 203
C. J. Doorenbos, M. R. Daha, E. Rijsdijk, and P. van Brummelen
A Highly Sensitive and Direct Radioimmunoassay of the Atrial Natriuretic Peptide in Human Plasma, Urine, and Cerebrospinal Fluid 206
K. Ando, H. Sakamoto, T. Masuda, K. Kihira, and F. Marumo

Plasma Immunoreactive Atrial Natriuretic Peptide Levels and Urinary Sodium Excretion Before, During and After Intravenous Saline Infusion in Normal Man 211

The Role of ANP in Acute Volume Expansion Investigated with a Monoclonal Antibody 214
C. Hirth, J-P Stasch, S. Kazda, and A. John

Effect of Narcotic Administration on Plasma Atrial Natriuretic Factor in Humans 219

Plasma Levels of Atrial Natriuretic Peptides Following Inhibition of Angiotensin Converting Enzyme and Kallikrein in the Rat 221
K. Peter Ohman, E. S. Marks, C. H. Weaver, N. Zamir, and H. R. Keiser

Section II: ANP Receptors and Second Messengers

Monoclonal Antibodies to the Rat Kidney ANF Receptor Block ANF Binding and Inhibit ANF Action 225
L. P. Laing, T. G. Flynn, C. C. Yip, and J. C. Roder

A Monoclonal Antibody Against Atrial Natriuretic Factor Receptor 229
I. Sen, P. Roy, and G. Colucci

Immunohistochemical Localization of ANP Receptor Sites in Bovine Kidney 232
K. Naruse, M. Naruse, H. Demura, and K. Shizume

Solubilized ANF Binding Sites from Bovine Intestinal Epithelium 237
D. F. Sellitti

Consequence of Down-Regulation of ANF Receptors on ANF-Induced cGMP Production 240
P. Roubert, M. O. Lonchampt, P. Plas, J. Goulin, P. E. Chabrier, and P. Braquet

Atrial Natriuretic Peptide Receptors in Thymus and Spleen of Young Spontaneously Hypertensive Rats 243
E. Castren, M. Kurihara, J. S. Gutkind, and J. M. Saavedra

Inhibition of Atrial Natriuretic Factor-Induced cGMP Accumulation by Phorbol Dibutyrate, an Activator of PKC 248
P. Nambi, M. Whitman, N. Aiyar, F. Stassen, and S. Crooke

Amiloride Potentiates Vascular Relaxation and cGMP Production via Atrial Natriuretic Factor by Increasing Receptor Binding to Vascular Tissue 250
U. Albus, W. Linz, G. Wiemer, G. Breipohl, and J. Knolle

Urinary Cyclic GMP as a Marker of the Renal Response to Atrial Natriuretic Peptide During Water Immersion 254
Possible Involvement of Cyclic GMP (cGMP) in ANP-Induced Natriuresis, Independent of Prostaglandins (PGs) in Kidney

Atrial Natriuretic Peptide Receptors in Rat Sympathetic Ganglia: Alterations in Genetically Hypertensive Rats
J. S. Gutkind, M. Kurihara, E. Castren, and J. M. Saavedra

The “ANF Test”: cGMP Responses to Injected ANF
H. Maimer, J-M Heim, J. Weil, and R. Gerzer

Effect of Different Atrial Natriuretic Peptides on Adenylyl Cyclase of Particular Brain Areas of Wistar-Kyoto Rats
H. Geiger, U. Bahner, M. Palkovits, and A. Heidland

Section III: ANP Effects on the Endocrine and Nervous Systems

Atrial Natriuretic Factor Inhibits Phosphorylation of Certain Proteins in the Plasma Membrane Fractions of Bovine Adrenal Cortex
K. N. Pandey, K. S. Misono, and T. Inagami

Atrial Natriuretic Factor Inhibits Angiotensin-Evoked Aldosterone Secretion without Affecting the Calcium Messenger System
A. Ganguly, S. Chiou, C. E. Gomez-Sanchez, and J. S. Davis

Role of Atrial Natriuretic Peptide in the Regulation of Aldosterone Secretion during Volume Expansion
M. Yamakado, M. Nagano, M. Umezu, H. Tagawa, Y. Hirata, and M. Ishii

Hypophysectomy Attenuates Acute Volume Expansion-Induced Release of Atrial Natriuretic Peptides from Cardiac Atria
N. Zamir, M. Haass, H. R. Keiser, and K. Peter Ohman

Effect of Treatment with L-Thyroxine on Plasma ANP Levels in Athyreotic Patients: Indirect Evidence for the Necessity of Adequate Thyroid Hormone Levels to Maintain Normal ANP Levels
M. Weissel, C. Punzengruber, E. Hartter, O. Burghuber, B. Ludvik, and W. Woloszczuk

Circulating Atrial Natriuretic Peptides in Rats with Experimentally Induced Hypo- and Hyperthyroidism
K. Peter Ohman, H. R. Keiser, and N. Zamir

Isolation and Characterization of an Active Sodium Transport Inhibitor (ASTI) from Adult Rat Hypothalamus and Pituitary
J. Kendall, S. Thomas, G. Spurlock, M. Lewis, K. Morgan, and M. Afzal Mir

Atrial Natriuretic Peptide: Influence of Beta-Adrenergic Stimulation on its Release in the Dog

Atrial Natriuretic Factor Production in Diabetes and Hypertrophied Hearts
B. H. L. Chua, C. C. Chua, and S. L. Rose

Absence of Diurnal Variation of Atrial Natriuretic Factor in the Human
CONTENTS

Increased Circulating Atrial Natriuretic Peptides in Copper Deficient Male Rats
S. J. Bhathena, B. W. Kennedy, P. A. Marsh, M. Fields, and N. Zamir

Distribution and Molecular Form of Atrial Natriuretic Polypeptide in Spinal Cord

Mechanism of Central Actions of Atrial Natriuretic Polypeptide (ANP)

The Presence of Atrial Natriuretic Peptide Demonstrated in Canine Cerebrospinal Fluid and the Brain as its Possible Origin
F. Marumo, T. Masuda, and K. Ando

Regulatory Roles of Brain ANP and Renin-Angiotensin Systems in ANP Secretion from Heart

Decreased Concentration of Atrial Natriuretic Peptides in Various Brain Areas of the Spontaneously Hypertensive Rat
U. Bahner, H. Geiger, M. Palkovits, and A. Heidland

ANF Antibody Reaction Is Greater in the Atria of Sympathectomized Male Rats Compared to Normal Controls
L. C. Zoller, L. Wright, and C. Waring

Section IV: ANP Effects on the Kidney and Liver

Atrial Natriuretic Peptide Is a Potential Mediator of Hyperfiltration in Diabetic Rats
F. V. Ortola, B. J. Ballermann, S. Anderson, and B. M. Brenner

Human Atrial Natriuretic Peptide Inhibits Tubular Effects of Antidiuretic Hormone in Humans
J. Brown, M. L. Forsling, and J. D. H. Slater

Renal Medullary Localization of the Renal Natriuretic Action of Atrial Natriuretic Peptide in Humans
W. M. T. Janssen, P. E. De Jong, G. K. van der Hem, and D. de Zeeuw

Renal Responses to Atrial Peptide: Genetics and Salt as Modulators
T. H. Steele, and L. Challoner-Hue

The Effect of Atrial Natriuretic Peptide on Developmental Renal Functions in Euvolemic and Volume-Loaded Puppies
E. G. John and L. Fornell

Atrial Natriuretic Peptide: Effects on Renal Tissue Catecholamines Following Renal Ischemia
S. G. Shaw, P. Weidmann, and J. Hodler
CONTENTS

Toxic Acute Renal Failure of Rats: Effects of Atrial Natriuretic Peptide (ANP) on Renal Function 375

E. Heidbreder, K. Schafferhans, N. Aktas, A. Heyd-Schramm, and A. Heidland

Renal Actions of Atrial Natriuretic Peptide in Gentamicin-Induced Acute Renal Failure 381

K. Schafferhans, E. Heidbreder, S. Sperber, J. Dämmrich, and A. Heidland

Regulation of Atrial Natriuretic Factor in Renal Failure 385


Renal Effects of Genetically Derived Atrial Natriuretic Factor in Anesthetized Rats 390

C. M. Harvey, N. Hancock, S. Hillicker, D. Schenk, J. Lewicki, R. L. Wendt, and R. W. Lappe

Atrial Natriuretic Factor Increases Prostacyclin Production in Hydronephrotic Rat Kidneys 392

S. I. Himmelstein, W. E. Yarger, and P. E. Klotman

Vasorelaxation and Natriuresis of Synthetic rANF Analogues 396


Renal Effects of Intranasal Administration of Anaritide in Anesthetized Dogs 400

R. A. Gabel, R. L. Wendt, and R. W. Lappe

High Levels of Atrial Natriuretic Peptide in Hemodialysis Patients: Volume Overload or Congestive Heart Failure? 404

T. Eisenhauser, J. Talartschik, G. Sold, E. Voth, M. Hansing, and F. Scheler

Renal Responses to Alpha-hANP Infusion in Patients with Congestive Heart Failure and in those with Chronic Renal Failure 408


Failure of Atrial Natriuretic Factor to Increase Average Capillary Permeability in Rats 412

N. C. Trippodo, and R. W. Barbee

Relationships between Atrial Natriuretic Factor Plasma Renin Activity and Plasma Volume in Cirrhotic Patients with and without Ascites 416

J. P. Vinel, P. H. Denoyel, P. E. Chabrier, I. Viossat, P. Cales, J. P. Caucanas, P. Braquet, and J. P. Pascal

Impaired Stimulation of ANF in Patients with Cirrhosis and Ascites 418


Plasma Levels of Human Atrial Natriuretic Peptide in Liver Cirrhosis Are Sensitive to Volume Expansion by Infusion and Peritoneovenous Shunt 422

Section V: ANP in Clinical Heart Disease

Gene Expression, Storage, and Release of Atrial Natriuretic Peptide in Rats with Myocardial Infarction


Atrial Natriuretic Peptide and Body Sodium in Rats with Chronic Myocardial Infarction

G. P. Hodsman, R. W. Harrison, and C. I. Johnston

Atrial Natriuretic Peptide in Rats with Heart Failure

I. Tikkanen, T. Tikkanen, M. Svarström-Fraser, H. Sariola, and F. Fyhrquist

Response to Synthetic Atrial Natriuretic Factor in Rats with Compensated and Uncompensated High-Output Heart Failure

A. Hoffman, J. Winaver, J. C. Burnett, and A. Haramati

Raised Plasma Levels of Atrial Natriuretic Peptide in Young and Aged Cardiomyopathic Hamsters


Atrial Natriuretic Polypeptide Secretion Is Stimulated by Atrial Pacing without Elevation of Atrial Pressure in Conscious Dogs with Complete Atrioventricular Block

K. Nishimura, K. Nakao, Y. Saito, H. Imura, and T. Ban

The Effect of Atriopeptin III on Pulmonary Surfactant and Respiratory Distress Syndrome in Rats


Atrial Natriuretic Polypeptide in Human and Rat Ventricles—Evidence for Augmented Gene Expression of ANP in Diseased Ventricle


Effects of Atrial Natriuretic Peptide on Left Ventricular Performance in Humans

M. Volpe, C. Indolfi, F. Piscione, A. Focaccio, M. Cappelli Bigazzi, B. Trimarco, and M. Chiariello

Nonselective Beta-Blockade and Effects of Volume Loading on Left-Ventricular Size and Release of ANP in Healthy Humans

P. V. Nguyen, D. L. Smith, A. Marquez-Julio, and F. H. H. Leenen

Plasma Levels of Atrial Natriuretic Peptide and Arginine Vasopressin during Induced Supraventricular Tachycardia in Humans

R-C Tsai, T. Yamaji, M. Ishibashi, F. Takaku, S-C Pang, S-J Yeh, Y-S Lee, J-S Hung, and D. Wu

Characteristics of Human Atrial Natriuretic Peptide Release During Exercise in Normal Persons, Cardiac Patients, and Endurance-Trained Athletes

D. H. Petzl, E. Hartter, D. Glogar, T. Rimpfl, W. Woloszczuk, and P. Haber
CONTENTS

The Hemodynamic Responses to Atrial Natriuretic Peptide in Congestive Heart Failure
R. Takeda, I. Miyamori, T. Morisse, S. Hifumi, and J. Mifune

Pharmacokinetics of α-Human Atrial Natriuretic Polypeptide and Effects of ANP Infusion on Plasma cGMP Level and Hemodynamics in Patients with Congestive Heart Failure

An Increase of β-Human Atrial Natriuretic Polypeptide in Failing Hearts

Release of Atrial Natriuretic Peptide (α-H-ANP 1–28) During Cardiac Arrest and After Resuscitation in 19 Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass
J. Talartschik, T. Eisenhauer, R. De Vivie, B. Talartschik, and F. Scheler

Atrial Natriuretic Peptide Concentrations at Rest and During Exercise in Patients with Pulmonary Artery Hypertension

Secretion Mechanism of Human Atrial Natriuretic Peptide in Patients with Ischemic Heart Disease

Human Atrial Natriuretic Peptide in Aortic and Coronary Sinus Blood During Atrial Pacing in Patients with Ischemic Heart Disease

Atriopeptin and Vasopressin Plasma Levels and Platelet Receptors in Congestive Heart Failure

Plasma Atrial Natriuretic Peptide in Heart Transplant Recipients
F. Fyhrquist, T. Forslund, I. Tikkanen, T. Fröysaker, E. Myhre, F. Riddervold, and S. Simonsen

Section VI: ANP in Hypertension

Effect of Simultaneous Infusion of Atrial Natriuretic Peptide and Angiotensin II on Blood Pressure in Rats
T. Forslund, T. Tikkanen, I. Tikkanen, and F. Fyhrquist

Potentiation of Renal Vasodilator Responses to Nitroglycerin During ANF Infusion in Conscious SHR
J. A. Todt, R. L. Wendt, and R. W. Lappe
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitroprusside but not ANF Inhibits Venoconstriction in an In Situ Rat Model</td>
<td>525</td>
</tr>
<tr>
<td>E. J. Sybertz, R. W. Watkins, and R. P. Tedesco</td>
<td></td>
</tr>
<tr>
<td>Chronic Effects of Synthetic Atrial Natriuretic Factor in Mineralocorticoid Hypertension in Rats</td>
<td>530</td>
</tr>
<tr>
<td>Effect of Calcium Diet and Parathyroidectomy on Atrial Natriuretic Peptide of Particular Brain Areas of Spontaneously Hypertensive Rats</td>
<td>534</td>
</tr>
<tr>
<td>H. Geiger, U. Bahner, M. Palkovits, B. Seewaldt, and A. Heidland</td>
<td></td>
</tr>
<tr>
<td>Tissue Levels of Immunoreactive Atrial Natriuretic Factor in Spontaneously Hypertensive and Normotensive Wistar Kyoto Rats Following Acute Volume Expansion</td>
<td>538</td>
</tr>
<tr>
<td>J. L. Sonnenberg, Y. Sakane, and R. Ghai</td>
<td></td>
</tr>
<tr>
<td>Atrial Natriuretic Factor in Hypertensive Humans</td>
<td>543</td>
</tr>
<tr>
<td>Effect of Volume Depletion and Repletion on Plasma Concentrations of Atrial Natriuretic Hormone in Essential Hypertension</td>
<td>547</td>
</tr>
<tr>
<td>G. H. Anderson, Jr., M. Miller, N. Blakeman, and D. H. P. Streten</td>
<td></td>
</tr>
<tr>
<td>Raised ANP-Plasma Levels in Essential Hypertension Indicate Left Atrial and Left Ventricular Involvement</td>
<td>552</td>
</tr>
<tr>
<td>G. Wambach, B. Goriben M. Stimpel, G. Bönner, and W. Kaufmann</td>
<td></td>
</tr>
<tr>
<td>Plasma Concentration of α-hANP and Renal and Endocrine Responses to α-hANP Infusion in Patients with Secondary Hypertension</td>
<td>555</td>
</tr>
<tr>
<td>Atrial Natriuretic Polypeptide in Essential Hypertension and Aldosteronism—Pharmacokinetics and Effects on Renal, Cardiovascular, and Endocrine Systems</td>
<td>559</td>
</tr>
<tr>
<td>Effects of Ketanserin on Blood Pressure, Plasma Atrial Natriuretic Factor, Plasma Renin Activity, and Aldosterone in Mild Essential Hypertension</td>
<td>564</td>
</tr>
<tr>
<td>P. Bielmann, J. Gutkowska, and G. Leduc</td>
<td></td>
</tr>
<tr>
<td>Salt Balance and Plasma Human Atrial Natriuretic Peptide in Patients with Essential Hypertension</td>
<td>567</td>
</tr>
<tr>
<td>T. Ogihara, H. Hara, J. Shima, K. Inunama, and Y. Kumahara</td>
<td></td>
</tr>
<tr>
<td>Therapeutic Actions of Alpha-Human Atrial Natriuretic Polypeptide in 17 Clinical Cases</td>
<td>570</td>
</tr>
</tbody>
</table>

**Section VII: ANP in Pregnancy and Neonates**

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma Atrial Natriuretic Peptide in Late Pregnancy and Puerperium</td>
<td>575</td>
</tr>
</tbody>
</table>
Plasma Levels of Atrial Natriuretic Peptide in Untreated Preeclampsia: Relationships with Cardiac Filling Pressures and Renin-Aldosterone
W. Visser, M. A. van den Dorpel, F. H. M. Derkx, H. C. S. Wallenburg, and M. A. D. H. Schalekamp

Plasma Levels of Alpha-hANP in Normal and Hypertensive Disease of Pregnancy

The Natriuretic Response to Atrial Natriuretic Factor Is Blunted in Newborn Puppies
A. Haramati and S. E. Mulroney

Elevated Atrial Natriuretic Peptide in Small Premature Infants

Cerebrospinal Fluid and Plasma Concentration of Atrial Natriuretic Peptide in Newborn Infants

Atrial Natriuretic Factor and Diuresis in the Human Newborn
S. Hulman, B. Falkner, M. Curtis-Cohen, and R. Grekin

Influence of ANP on Fluid Homeostasis in Infants: Measurement of ANP and cGMP Levels in Plasma and Urine
J. Weil, J. M. Heim, M. Brügmann, T. M. Strom, M. Haufe, and R. Gerzer

Subject Index
IMPAIRED STIMULATION OF ANF IN PATIENTS WITH CIRRHOSIS AND ASCITES


Departments of Medicine II and I, Klinikum Großhadern, University of Munich, D-8000 Munich, Federal Republic of Germany

The pathophysiology of renal sodium retention and ascites formation in patients with cirrhosis of the liver has become rather perplexing. There is increasing evidence that activation of the renin-aldosterone system is just one of several factors involved in the impaired volume regulation of cirrhosis. For many years, a deficiency of a putative natriuretic hormone in cirrhosis has been postulated but never satisfactorily demonstrated. Therefore, investigations of the role of atrial natriuretic factor (ANF) in cirrhosis have been eagerly awaited.

The first communication on ANF plasma levels in cirrhosis showed that there is no absolute deficiency of this novel natriuretic and diuretic hormone in patients with cirrhosis (1). These findings have been confirmed by several groups, reporting ANF plasma levels in patients with cirrhosis and ascites equal to or higher than normal (2).

However, the immunoreactive ANF in plasma of patients with cirrhosis might comprise different molecular species with altered biological activity, as has been suggested in patients with congestive heart failure (3). By high performance gel permeation chromatography only negligible amounts of immunoreactivity coeluting with precursor forms of ANF 99–126 have been detected (4). Thus, no evidence for major abnormalities of processing of ANF was found in cirrhosis.

Neither basal plasma levels nor characterization of immunoreactivity necessarily reflect the functional status or the compensatory reactivity of the ANF system. Therefore, in the present study responsiveness of the ANF system to volume stimulation was investigated. Head-out water immersion (WI) into a thermoneutral bath has been shown to induce central hypervolemia with atrial distension and to prompt natriuresis and diuresis (5). Epstein and others have demonstrated in numerous investigations that WI is a useful tool for the study of volume regulation (6): it increases central volume by shifting blood from peripheral vessels thus obviating the necessity of infusing volume expanders that might alter plasma...
ANP EFFECTS ON THE KIDNEY AND LIVER

composition. We demonstrated that WI rapidly increases ANF plasma levels in healthy human subjects (7). In the present study WI was used to investigate the response of ANF to acute volume stimulation in patients with cirrhosis.

PATIENTS AND METHODS

Twenty-five healthy controls and 21 patients with cirrhosis, 10 with and 11 without ascites, were investigated after informed consent had been obtained. There was no evidence for cardiovascular, renal, or pulmonary disease in controls or patients. No diuretics had been given to any subject for 1 week preceding the study. Subjects were on a hospital diet containing approximately 150 mEq sodium/day and were prohibited alcohol, tobacco, tea, and coffee the day before and during the experiment. In the morning after complete emptying of the bladder, a catheter was placed in a forearm vein, subjects were given 400 ml of water orally and assumed a seated position next to a tank with thermoneutral (34.5 ± 0.2°C) water. After 1 hr the subjects were immersed to their neck into the water bath, maintaining the same position for 1 hr. This was followed by another hour of sitting outside the tank. Throughout the investigation, 200 ml/hr of water were given orally to ensure adequate urine flow. Urine obtained by spontaneous emptying of the bladder was collected before (0), after 60 min (60 min), and 60 min subsequent to (120 min) the end of WI. Blood samples were obtained at 0, 60 min, and 120 min. ANF was determined in extracted plasma samples as described before (4).

Data are given as mean and standard error. Data were evaluated statistically by paired or unpaired Students t-test.

RESULTS

Volume stimulation by WI caused a rise of plasma ANF from 6.0 ± 0.6 fmol/ml to 13.6 ± 2.6 fmol/ml in healthy subjects and from 8.5 ± 1.3 fmol/ml to 16.5 ± 2.6 fmol/ml in cirrhotic patients without ascites; increases were significant at the 0.01 level. In cirrhotics with ascites, stimulation of ANF from 7.7 ± 1.3 fmol/ml to 11.4 ± 2.3 fmol/ml was significantly (p < 0.05) blunted as compared to cirrhotics without ascites (Fig. 1A).

Renal response to immersion is illustrated in Fig. 1B and C. Mean increases in urinary volume were found to be 3.64 ± 0.60 ml/min in controls, 2.02 ± 0.81 ml/min in cirrhotics without ascites, and only 0.68 ± 0.35 ml/min—not significantly different from baseline values—in cirrhotics with ascites. Similar differences were observed in urinary sodium excretion: immersion induced a rise by 146 ± 38 µmol/min in controls, by 75 ± 43 µmol/min in cirrhotics without ascites, and by only 43 ± 19 µmol/min in cirrhotics with ascites. Increases in both cirrhotic groups did not reach the level of significance.

DISCUSSION

The observation that WI significantly increases ANF plasma levels in a larger number of healthy subjects is in accordance with previous results from our laboratory and has been confirmed by other investigators (8–11). Similar increases were observed in patients
with cirrhosis of the liver without ascites. In cirrhotics with ascites, however, stimulation of ANF release into plasma was found to be significantly reduced after 1 hr immersion. This might be due to a decreased volume stimulus in these patients. However, plasma renin activity as an indicator of centrally effective volume decreased in cirrhotics with ascites by a ratio not different from that in cirrhotics without ascites or controls (unpublished observations). Furthermore, central hemodynamics and intracardiac pressures are influenced by WI independent of the degree of ascites (12). Thus, blunted increase of atrial pressure
as a stimulus for ANF release does not seem a likely explanation for the observed blunted ANF stimulation in these patients. Therefore, a defect of ANF synthesis, release, or metabolism might be suspected in these patients.

The blunted ANF stimulation is paralleled by reduced increases of urinary sodium excretion and urinary volume following immersion in cirrhotics with ascites. Although this might suggest a (patho-) physiological role of ANF in volume regulation, no correlations of either basal or stimulated ANF with renal response could be found. In view of the involvement of several other hormonal systems in volume regulation, however, this finding is not surprising.

Furthermore, at comparable baseline plasma levels of ANF, excretion of sodium was diminished in cirrhotic patients as compared to controls and in patients with ascites as compared to patients without ascites. The renal response to stimulation by water immersion was less marked than the increase of ANF in the cirrhotic groups. These findings might be consistent with increased activity of sodium retaining principles, counteracting the renal action of ANF, or a blunted responsiveness of the kidney to ANF in cirrhosis.

This study demonstrates a blunted response of ANF release to WI in patients with cirrhosis of the liver and ascites and might suggest a role for this novel hormone in impairment of acute volume regulation in cirrhosis.

REFERENCES


